HHS Proposes New Access Policy for Peptide Compounding
The proposed plan would allow pharmacies to compound certain restricted peptides under new enforcement discretion rules.
Updated on Oct. 15, 2026 in Healthcare
Live Poll
Should the federal government allow pharmacies to produce peptides that lack FDA approval?
The U.S. Department of Health and Human Services has submitted a proposal to the Office of Management and Budget that would allow compounding pharmacies to produce certain peptides. This interim policy aims to address access to substances like BPC-157 that were previously restricted by the FDA.
Why it matters
The proposal seeks to provide a regulated alternative to the gray market of imported peptides while potentially opening a significant new revenue stream for pharmacy operators and telehealth providers. It follows a July 2026 advisory panel recommendation to ease constraints on most of the seven substances reviewed.
An external advisory panel recommended lifting restrictions on 6 out of 7 peptides reviewed in July 2026. Analysts estimate the total market value for these compounds could reach between $2 billion and $3 billion.
The players
U.S. Department of Health and Human Services
The federal agency responsible for developing and implementing health policies and regulatory access frameworks.
FDA
The federal agency that regulates compounding pharmacy practices and evaluates the safety profile of injectable substances.
Hims & Hers
A digital health company that provides subscription-based access to personalized medical treatments and wellness products.
Noom
A digital health platform that combines behavioral coaching with clinical services and health-related interventions.
The details
The interim access policy utilizes enforcement discretion, a mechanism that permits the FDA to selectively decline enforcement actions against pharmacies compounding specific substances. By formalizing this approach, the government aims to shift patient sourcing away from unregulated foreign imports toward domestic pharmacy channels. If approved by the Office of Management and Budget, the policy would create a framework for telehealth providers like Hims & Hers and Noom to legally integrate these compounds into their offerings.
Timeline
July 2026: An external FDA panel recommended easing restrictions on six out of seven reviewed peptides.
October 8, 2026: HHS submitted the interim access policy to the Office of Management and Budget for review.
Market Landscape
The proposed policy marks a notable shift from current FDA compounded drug list restrictions, which previously prohibited pharmacy production of these substances. It follows a pattern of evolving federal stances on pharmaceutical compounding as market demand for niche therapeutic products accelerates.
Pharmacy and telehealth operators should monitor the Office of Management and Budget review process for finalized enforcement guidelines on peptide compounding. Businesses should verify with legal counsel that any inventory expansion complies with current FDA status until official policy changes are codified.
The takeaway
This policy pivot signals a potential transition from total restrictions to a controlled regulatory environment for popular injectables. Operators should track the Office of Management and Budget’s review, as a favorable outcome would provide the first clear federal compliance path for compounding these products.
Further reading
For broader trends in drug access and regulatory shifts, see the latest Healthcare analysis.
Live Poll
Should the federal government allow pharmacies to produce peptides that lack FDA approval?
